Vertex Pharmaceuticals said on Monday it will not continue development of its experimental non-opioid painkiller as a solo ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...

Move your 401k to Robinhood and get a 3% match on deposits. Vertex ended the quarter with $11.4 billion in cash, cash equivalents and marketable securities, up from $11.2 billion at the end of 2024.

Vertex Pharmaceuticals ( NASDAQ: VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet ...

For the full year, analysts expect VRTX to report EPS of $15.67, up significantly from a loss of $1.35 per share in fiscal 2024. Its EPS is expected to further grow 12.4% year-over-year to $17.61 ...

Gemini 1.5 Flash becoming generally available, a preview of Imagen 3 and a context caching feature preview are some of the latest news for Google Cloud’s Vertex AI ML platform.